- Dallah Healthcare’s annual profits for the fiscal year fell short of expectations.
- Reported profit was 471.2 million riyals, marking a 31% increase from the previous year, but still below the forecast of 485.1 million riyals.
- Total revenue reached 3.21 billion riyals, which was slightly less than the anticipated 3.31 billion riyals.
- Operating profit was recorded at 567.1 million riyals.
- Earnings per share (EPS) stood at 4.83 riyals.
- Analyst recommendations comprised two buy ratings, seven hold ratings, and three sell ratings.
A look at Dallah Healthcare Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, Dallah Healthcare Co has a mixed outlook for the long term. With a solid Growth score of 4, the company is expected to experience positive expansion and development in the future. This indicates potential for Dallah Healthcare Co to grow its operations and increase its market share in the healthcare industry. Additionally, the company has received a Value score of 3, suggesting that it may be undervalued relative to its intrinsic worth, potentially presenting an opportunity for investors.
On the other hand, Dallah Healthcare Co received lower scores in Dividend and Momentum, with scores of 2 for each. This implies the company may not be as attractive in terms of dividend payments and may lack strong market momentum compared to its peers. However, with a Resilience score of 3, Dallah Healthcare Co is deemed to have a moderate capacity to weather market fluctuations and challenges. Overall, Dallah Healthcare Co‘s outlook appears to be promising for growth but may require closer monitoring in terms of dividends and market momentum.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
